Design of wide-spectrum inhibitors targeting coronavirus main proteases.
The genus Coronavirus contains about 25 species of coronaviruses (CoVs), which are important pathogens causing highly prevalent diseases and often severe or fatal in humans and animals. No licensed specific drugs are available to prevent their infection. Different host receptors for cellular entry,...
Main Authors: | Haitao Yang, Weiqing Xie, Xiaoyu Xue, Kailin Yang, Jing Ma, Wenxue Liang, Qi Zhao, Zhe Zhou, Duanqing Pei, John Ziebuhr, Rolf Hilgenfeld, Kwok Yung Yuen, Luet Wong, Guangxia Gao, Saijuan Chen, Zhu Chen, Dawei Ma, Mark Bartlam, Zihe Rao |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2005-10-01
|
Series: | PLoS Biology |
Online Access: | https://doi.org/10.1371/journal.pbio.0030324 |
Similar Items
-
Recent Progress in the Drug Development Targeting SARS-CoV-2 Main Protease as Treatment for COVID-19
by: Wen Cui, et al.
Published: (2020-12-01) -
From Repurposing to Redesign: Optimization of Boceprevir to Highly Potent Inhibitors of the SARS-CoV-2 Main Protease
by: Matthias Göhl, et al.
Published: (2022-07-01) -
Irreversible inhibitors of the 3C protease of Coxsackie virus through templated assembly of protein-binding fragments
by: Daniel Becker, et al.
Published: (2016-09-01) -
Effects of NS2B-NS3 protease and furin inhibition on West Nile and Dengue virus replication
by: Jenny Kouretova, et al.
Published: (2017-01-01) -
Identification of a Dual Inhibitor of Secreted Phospholipase A<sub>2</sub> (GIIA sPLA<sub>2</sub>) and SARS-CoV-2 Main Protease
by: Maria A. Theodoropoulou, et al.
Published: (2022-08-01)